| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2025―Aug―20 |
Natural Marine-derived Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease: A Comprehensive Computational Study |
Ghazal Nowroozi, Shokoufeh Rahmani, Parvin Jalali, Armin Zareie, Zahra Asvar, Amin Nowroozi |
| 2 |
[GO] |
2025―Apr―08 |
Investigation of the Therapeutic Effect of Remdesivir on Rapoport Shunt and Oxygen Delivery in Patients with COVID-19 |
Shahrzad Sharifpour Vajari, Fereshteh Atabi, Abdolreza Sabokrouh |
| 3 |
[GO] |
2025―Feb―15 |
Atorvastatin Attenuated the Inflammatory Outcomes of COVID-19: A Double-Blind, Randomized Controlled Trial |
Hajar Shokri-Afra, Shahab Moghadam, Ziaeddin Oladi, Masoud Lotfizadeh, Mohammad Mehdi Mirforoughi, Mohammad-Hassan Arjmand, Ahmad Raeisi |
| 4 |
[GO] |
2024―Okt―13 |
The Impact of United Kingdom SARS-CoV-2 Spike Mutations on Spike-ACE2 Interactions Investigated Through Molecular Dynamic Simulation |
Zohreh Salehi, Mohammad Ali Hosseinpour Feizi, Reza Safaralizadeh, Mohsen Shahlaei |
| 5 |
[GO] |
2024―Sep―07 |
Potential of the Triad of Fatty Acids, Polyphenols, and Prebiotics from Cucurbita against COVID-19 in Diabetic Patients |
Qushmua E. Alzahrani, Richard B. Gillis, Stephen E. Harding, Luciano Henrique Pinto, Monica Gulati, Bhupinder Kapoor, Pooja Rani, Sachin Kumar Singh, Gary G. Adams |
| 6 |
[GO] |
2022―Dez―22 |
Dose kelofan syrup effective for clinical symptoms and biochemical factorsin COVID-19 patients? A double-blind clinical trials |
Ramin Nasimi Doost Azgomi, ArezooMoini Jazani, Shahram Habibzadeh, Hamidreza Nasimi Doost Azgomi, Alireza Nasimi Doost Azgomi, Moharram Aghabalaii |
| 7 |
[GO] |
2022―Dez―22 |
The alkaloids of Isatis indigotica as promising candidates against COVID-19: A molecular docking simulation for drug development |
Saba Hadidi, MohammadBagher Majnooni, Farnoosh Kazemi, Mahdi Mojarrab, Gholamreza Bahrami, SeyedShahram Miraghaei |
| 8 |
[GO] |
2021―Dez―17 |
Clinical effectiveness and safety of sofosbuvir-velpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial |
Reza Khodarahmi, Babak Sayad, Masomeh Mehrabi, Farid Najafi, Ronak Miladi, Zeinab Mohseni Afshar, Feizollah Mansouri, Maria Shirvani, Mehdi Salimi, FatemehKhosravi Shadmani |
| 9 |
[GO] |
2021―Jun―16 |
Management of COVID-19 by phytotherapy: A pharmacological viewpoint |
Ayesheh Enayati, Mahdieh Eftekhari, Aref Salehi |
|
